Is there another Plavix out there? That was the question on everyones’ mind as they watched Bristol-Myers Squibb’s settlement with Apotex unravel with devastating speed. (See "The War on Generics – Part I," in this issue. [A#])
Speculation among investors immediately focused on Cephalon Inc. and its settlements with the four companies who first challenged a...




